Business mix
- It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair.
- The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products.
- It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types.
- The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Current key questions
- Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
- How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
- Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
